Physiological SCFAs may confer indirect anti-synuclein benefit through an enter…

Mechanistic description

At realistic exposure levels, SCFAs are more likely to act as receptor-mediated endocrine signals than as direct neuronal epigenetic modulators. Activation of intestinal FFAR2/FFAR3 on L cells could raise GLP-1 signaling and secondarily improve neuronal stress resistance or proteostasis, but the current evidence supports mediation plausibility more than proven alpha-synuclein clearance.

Mechanism / pathway

FFAR2/FFAR3/GLP1R
→
neurodegeneration

Evidence for (3)

SCFAs are established ligands for GPR41/GPR43, providing a plausible receptor-level mechanism at physiologic concentrations.

PMID:12496283
Butyrate-associated benefit in PD models has been linked with increased GLP-1 signaling, supporting an indirect endocrine pathway.

PMID:28991675
A rotenone model showed sodium butyrate benefit alongside GLP-1-related changes, consistent with but not proving mediation.

PMID:36761177

Evidence against (2)

Available studies used pharmacologic sodium butyrate and do not demonstrate that physiologic micromolar exposure is sufficient for meaningful alpha-synuclein clearance.

PMID:36761177
Low circulating SCFA levels and compartment differences make translational dose matching uncertain.

PMID:35091760

Evidence matrix

3 supporting 2 contradicting

53% posterior support

Supporting

SCFAs are established ligands for GPR41/GPR43, providing a plausible receptor-level mechanism at physiologic concentrations. PMID:12496283
Butyrate-associated benefit in PD models has been linked with increased GLP-1 signaling, supporting an indirect endocrine pathway. PMID:28991675
A rotenone model showed sodium butyrate benefit alongside GLP-1-related changes, consistent with but not proving mediation. PMID:36761177

Contradicting

Available studies used pharmacologic sodium butyrate and do not demonstrate that physiologic micromolar exposure is sufficient for meaningful alpha-synuclein clearance. PMID:36761177
Low circulating SCFA levels and compartment differences make translational dose matching uncertain. PMID:35091760

Bayesian persona consensus

53% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). Physiological SCFAs may confer indirect anti-synuclein benefit through an enter…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-ca6480add4

BibTeX

@misc{scidex_hypothesis_hca6480a,
  title        = {Physiological SCFAs may confer indirect anti-synuclein benefit through an enter…},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-ca6480add4},
  note         = {SciDEX artifact hypothesis:h-ca6480add4}
}